Sphera Funds Management Ltd. Fate Therapeutics Inc Transaction History

Sphera Funds Management Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $1.59 Million - $3.79 Million	-89,425 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $2.85 Million - $5.79 Million	-96,051 Reduced 51.79%	89,425 $3.47 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $1.62 Million - $2.18 Million	-33,823 Reduced 15.42%	185,476 $10.9 Million
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $3.2 Million - $5.17 Million	54,000 Added 32.67%	219,299 $13 Million
Q2 2021 Aug 17, 2021	BUY	$67.25 - $92.52 $3.73 Million - $5.13 Million	55,492 Added 50.54%	165,299 $14.3 Million
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $2.01 Million - $3.26 Million	27,807 Added 33.91%	109,807 $9.05 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $4.04 Million - $10.7 Million	-106,000 Reduced 56.38%	82,000 $7.46 Million
Q3 2020 Nov 12, 2020	SELL	$30.41 - $40.5 $1.13 Million - $1.5 Million	-37,000 Reduced 16.44%	188,000 $7.51 Million
Q2 2020 Aug 13, 2020	BUY	$20.21 - $35.23 $4.55 Million - $7.93 Million	225,000 New	225,000 $7.72 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $163M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.